Elutia Inc.(ELUT)Earnings, Financials & Key Ratios

ELUT•NASDAQ

$0.95

Price updated Jul 6, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryRegenerative Medicine and Tissue Engineering

AboutElutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.Show more

Revenue$12M-49.6%
EBITDA-$16M+51.5%
Net Income$53M+198.9%
EPS (Diluted)-0.79+57.5%
Gross Margin53.66%+22.2%
EBITDA Margin-127.12%+3.8%
Operating Margin-149.78%-2.4%
Net Margin434.23%+296.2%
ROE192.9%

ELUT Price & Volume

Elutia Inc. (ELUT) stock price & volume — 10-year historical chart

Loading chart...

Strategic Divestiture Masks Persistent Operational Cash Burn

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Burning

Primary Risk:Binary product pipeline dependency

Key Thesis Takeaways

Elutia is currently navigating a high-risk transition toward a specialized drug-eluting biologic platform, a pivot that has resulted in a 48.4% year-over-year revenue contraction as of 2026Q1.
While the divestiture of legacy assets has temporarily improved the balance sheet, the company continues to face significant operational headwinds, evidenced by a deeply negative operating margin of -184.4%.
Investors should remain cautious as the firm's long-term viability depends on its ability to scale its core cardiac envelope portfolio while managing a persistent quarterly cash burn of $8.3 million.

Verdict Logic

the company's reliance on non-recurring divestiture proceeds to mask an underlying $8.3 million quarterly free cash flow burn suggests that the current business model lacks sustainable operational profitability.

ELUT Growth Metrics

Elutia Inc. (ELUT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-22.04%

3 Years-19.82%

TTM-32.64%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM224.96%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM144.56%

Return on Capital

10 Years-81.32%

5 Years-121.2%

3 Years-166.49%

Last Year-103.6%

Peers Comparison

Key metrics vs top competitors for Elutia Inc. (ELUT)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
ELUTElutia Inc.Current	$0.95	$41.9M	-1.20	-49.57%	434.23%	192.9%	—
NVCRNovoCure Limited	$17.32	$1.97B	-14.20	8.28%	-25.66%	-50.82%	—
XTNTXtant Medical Holdings, Inc.	$0.42	$58.49M	13.90	14.21%	1.5%	3.68%	—
OSBCOld Second Bancorp, Inc.	$23.22	$1.19B	14.33	18.09%	20.22%	10.2%	—
LMATLeMaitre Vascular, Inc.	$103.72	$2.36B	41.16	13.53%	24.35%	16.19%	—
MDTMedtronic plc	$83.06	$106.64B	22.27	8.43%	13.2%	9.78%	—